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Abstract
In 2009 the ﬁrst European Society of Clinical Microbiology and Infection (ESCMID) treatment guidance document for Clostridium difﬁcile
infection (CDI) was published. The guideline has been applied widely in clinical practice. In this document an update and review on the
comparative effectiveness of the currently available treatment modalities of CDI is given, thereby providing evidence-based
recommendations on this issue. A computerized literature search was carried out to investigate randomized and non-randomized trials
investigating the effect of an intervention on the clinical outcome of CDI. The Grades of Recommendation Assessment, Development and
Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The ESCMID and an
international team of experts from 11 European countries supported the process. To improve clinical guidance in the treatment of CDI,
recommendations are speciﬁed for various patient groups, e.g. initial non-severe disease, severe CDI, ﬁrst recurrence or risk for recurrent
disease, multiple recurrences and treatment of CDI when oral administration is not possible. Treatment options that are reviewed include:
antibiotics, toxin-binding resins and polymers, immunotherapy, probiotics, and faecal or bacterial intestinal transplantation. Except for very
mild CDI that is clearly induced by antibiotic usage antibiotic treatment is advised. The main antibiotics that are recommended are
metronidazole, vancomycin and ﬁdaxomicin. Faecal transplantation is strongly recommended for multiple recurrent CDI. In case of
perforation of the colon and/or systemic inﬂammation and deteriorating clinical condition despite antibiotic therapy, total abdominal
colectomy or diverting loop ileostomy combined with colonic lavage is recommended.
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Introduction
The previous European Society of Clinical Microbiology and
Infection (ESCMID) guidance document, which has been applied
widely in clinical practice, dates from 2009 [1]. Meanwhile, new
treatments for Clostridium difﬁcile infection (CDI) have been
developed and limitations of the currently recommended
treatment options of CDI are considered. As the current
ESCMID treatment guidance document is already implemented
in clinical practice, an update of this widely applied guidance
document is essential to further improve uniformity of national
hospital infection treatment policies for CDI in Europe. In
particular, after the recent development of new alternative
drugs for the treatment of CDI (e.g. ﬁdaxomicin) in the USA and
Europe, there has been an increasing need for an update on the
comparative effectiveness of the currently available antibiotic
agents in the treatment of CDI, thereby providing evi-
dence-based recommendations on this issue.
The objectives of this document are to:
1. Provide an overviewof currently availableCDI treatment options
2. Develop an evidence-based update of treatment recommen-
dations
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Update Methodology
Studies on CDI treatment were found with a computerized
literature search of PUBMED and Google Scholar using the
terms ‘Clostridium difﬁcile AND (treatment OR trial)’. All
randomized and non-randomized trials investigating the effect
of an intervention on the clinical outcome (resolution or
recurrence of diarrhoea; incidence of complications) of CDI
published in any language were included. Studies investigating
carriage or other purely microbiological parameters were not
considered sufﬁcient evidence for treatment strategies. The
resulting literature from 1978 was reviewed and analysed.
Furthermore, systematic reviews from the most recent
Cochrane analysis [2] and the up-dated guidelines of the
Infectious Diseases Society of America, the Australasian
Society for Infectious Diseases, the American College of
Gastroenterology, and the Health Protection Agency/Public
Health England guidance document (http://www.hpa.org.uk)
were evaluated [3–5]. Recommendations were based on a
systematic assessment of the quality of evidence. The Grades
of Recommendation Assessment, Development and Evaluation
(GRADE) system was used to grade the strength of our
recommendations and the quality of the evidence [6,7].
Draft versions of the guideline were written by the
executive committee (consisting of: S. Debast, M. Bauer and
E. Kuijper) and criticized by the Executive Committee and
advisors. After this, consensus was reached, resulting in the
ﬁnal version. The methods to evaluate the quality of evidence
and to reach group consensus recommendations were based
on the method described by Ullmann et al. [8].
Deﬁnition of the strength of recommendation is given in
Table 1. The quality of the published evidence is deﬁned in
Table 2a. Grouping quality of evidence into three levels only
may lead to diverse types of published evidence being assigned
speciﬁcally to a level II. To increase transparency in the
evaluation of the evidence an index (Table 2b) to the level II
recommendations was added where appropriate.
The guideline followed the Appraisal of Guidelines Research
and Evaluation Collaboration (AGREE) self-assessment tool
[9].
Deﬁnitions
Diagnosis
The diagnosis of CDI is based on (1) a combination of signs and
symptoms, conﬁrmed by microbiological evidence of C. difﬁcile
toxin and toxin-producing C. difﬁcile in stools, in the absence of
another cause, or (ii) colonoscopic or histopathological
ﬁndings demonstrating pseudomembranous colitis [1,3,10–12].
There are many different approaches that can be used in the
laboratory diagnosis of CDI; however, the best standard
laboratory test for diagnosis has not been established.
Diagnostic tests for CDI include: (i) detection of C. difﬁcile
products: cell culture cytoxicity assay (CCA), glutamate
dehydrogenase (GDH) and Toxins A and/or B, (ii) toxigenic
culture of C. difﬁcile, and (iii) nucleic acid ampliﬁcation tests
(NAAT): 16S RNA, toxin genes, GDH genes. Preferably a two-
or three-stage algorithm is performed to diagnose CDI, in
which a positive ﬁrst test is conﬁrmed with one or two
conﬁrmatory tests or a reference method [3,4,12,13]. Faeces
samples could be investigated with an enzyme immunoassay
detecting GDH, an enzyme immunoassay detecting toxins A
and B, or NAAT detecting Toxin B (TcdB). Samples with a
negative test result can be reported as negative. Faeces
samples with a positive ﬁrst test result should be re-tested
with a method to detect free faeces toxins, or with a method
to detect GDH or toxin genes, dependent on the assay applied
as ﬁrst screening test. If free faeces toxins are absent but
C. difﬁcle TcdB gene or GDH are present, CDI cannot be
differentiated from asymptomatic colonization. Recently, a
large study was presented in which several diagnostic
algorithms were evaluated to optimize the laboratory diagno-
sis of CDI [14]. The investigators concluded that two-stage
algorithms improve diagnosis of CDI. Two commonly recom-
mended methods in the laboratory diagnosis of CDI are the use
of GDH detection in stools as a means of screening for CDI,
conﬁrmed by NAAT such as PCR to detect toxigenic strains of
C. difﬁcile [4,12]. Furthermore, patients with a positive stool
toxin had C. difﬁcile disease with an increased risk of mortality
compared with patients with only a positive toxigenic culture,
thereby implying that stool toxin testing should be included in a
testing algorithm to optimize C. difﬁcile diagnostic testing [15].
Diarrhoea is deﬁned as loose stools, i.e. taking the shape of
the receptacle or corresponding to Bristol stool chart types 5–
7, plus a stool frequency of three stools in 24 or fewer
consecutive hours or more frequently than is normal for the
individual (deﬁnition World Health Organization, http://www.
who.int/topics/diarrhoea) [1,3,16–18].
Clinical pictures compatible with CDI are summarized in
Table 3.
TABLE 1. Deﬁnition of the Strength of Recommendation
Grade (SoR) ESCMID (adapted from ref. [8])
Strength Deﬁnition
A Strongly supports a recommendation for use
B Moderately supports a recommendation for use
C Marginally supports a recommendation for use
D Supports a recommendation AGAINST use
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Deﬁnition of Clostridium difﬁcile infection. An episode of CDI is
deﬁned as:
A clinical picture compatible with CDI and microbiological
evidence of free toxins and the presence of C. difﬁcile in stool
without reasonable evidence of another cause of diarrhoea.
or
Pseudomembranous colitis as diagnosed during endoscopy,
after colectomy or on autopsy [3,11,19].
Treatment response
Deﬁnition of treatment response. Treatment response is present
when either stool frequency decreases or stool consistency
improves and parameters of disease severity (clinical, labora-
tory, radiological) improve and no new signs of severe disease
develop. In all other cases, treatment is considered a failure.
Treatment response should be observed daily and evaluated
after at least 3 days, assuming that the patient is not worsening
on treatment. Treatment with metronidazole, in particular,
may result in a clinical response only after 3–5 days [21–23].
After clinical response, it may take weeks for stool consistency
and frequency to become entirely normal [23,24].
Recurrences
Deﬁnition of recurrent Clostridium difﬁcile infection. Recurrence
is present when CDI re-occurs within 8 weeks after the onset
of a previous episode, provided the symptoms from the
previous episode resolved after completion of initial treatment
[4,11].
It is not feasible to distinguish recurrence due to relapse
(renewed symptoms from already present CDI) from
recurrence due to reinfection in daily practice [20,25–28].
Severity of disease
Deﬁnition of severe Clostridium difﬁcile infection. Severe CDI is
deﬁned as an episode of CDI with (one or more speciﬁc signs
and symptoms of) severe colitis or a complicated course of
disease, with signiﬁcant systemic toxin effects and shock,
resulting in need for ICU admission, colectomy or death
[1,4,29].
Clostridium difﬁcile infection without signs of severe colitis in
patients with greater age (≥65 years), serious comorbidity,
Intensive Care Unit (ICU) admission, or immunodeﬁciency
may also be considered at increased risk of severe CDI
[30,31].
An overview of characteristics in patients with CDI that are
assumed to correlate with the severity of colitis is given in
Table 4 [32–39]. We must stress that the prognostic value of
these markers is uncertain.
Clinical prediction markers
Evidence. Clinical studies indicate superiority of speciﬁc treat-
ment strategies depending on the severity of disease. In
addition, alternative treatment options have been developed,
that may be more effective in preventing recurrence of disease.
Unfortunately some of the novel treatment strategies can be
very expensive, and may only be cost-effective for a certain
group of patients depending on the stage and severity of
disease. This emphasizes the importance for better identiﬁca-
tion of clinical markers, preferably early in the course of
disease, which might predict the beneﬁt from speciﬁc treatment
regimens to decrease CDI-related complications, mortality or
recurrences. Surprisingly little prospective and validated
research has been performed on clinical predictors of outcome
[40]. Furthermore, for some complications of CDI, such as ICU
admission or death, it is difﬁcult to determine to what extent
the complication can be attributed to CDI as opposed to the
presenting acute illness(es) or comorbidities.
A wide variety of risk factors for severe or recurrent CDI
have been suggested in literature, which makes it difﬁcult to
set a rigid clinical prediction rule [1,25,41–46]. Recently, a
TABLE 2. Deﬁnition of the Quality of Evidence (QoE)
ESCMID. Adapted from ref. [8]
Quality
of evidence Deﬁnition
2a: Level
I Evidence from at least one properly designed randomized,
controlled trial.
II Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case–control analytic studies
(preferably from more than one centre); from multiple time
series; or from dramatic results of uncontrolled experiments.
III Evidence from opinions of respected authorities, based on
clinical experience, descriptive case studies, or reports of
expert committees.
2b: Index
r Meta-analysis or systematic review of randomized controlled
trials.
t Transferred evidence, i.e. results from different patient cohorts,
or similar immune-status situation.
h Comparator group is a historical control.
u Uncontrolled trial.
a Abstract or poster of a study published at an international
meeting.
TABLE 3. Clinical pictures compatible with Clostridium difﬁ-
cile infection. Adapted from refs [1,3,11,19,20]
Sign/symptom Deﬁnition
Diarrhoea Loose stools, i.e. taking the shape of the receptacle or
corresponding to Bristol stool chart types 5–7, plus a stool
frequency of three stools in 24 or fewer consecutive hours
or more frequently than is normal for the individual.
Ileus Signs of severely disturbed bowel function such as vomiting
and absence of stool with radiological signs of bowel
distension.
Toxic megacolon Radiological signs of distension of the colon (>6 cm in
transverse width of colon) and signs of a severe systemic
inﬂammatory response.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 2), 1–26
CMI Debast et al. Treatment guideline for C. difﬁcile infection 3
systematic review was performed to derive and validate clinical
rules to predict recurrences, complications and mortality [46].
Most studies were found to have a high risk of bias because of
small sample sizes and much heterogeneity in the variables
used, except for leucocytosis, serum albumin and age [46].
Bauer et al. used a database of two randomized controlled
trials, which contained information for a large patient group
(1105 patients) with CDI, to investigate the prognostic value of
three markers for severe CDI. They found that both
leucocytosis and renal failure are useful predictors of a
complicated course of CDI, if measured on the day of
diagnosis [45].
A recent meta-analysis of two pivotal randomized con-
trolled trials comparing ﬁdaxomicin and vancomycin revealed
previous vancomycin or metronidazole treatment in the 24 h
before randomization, low eosinophil count (<0.1 9 109/L)
and low albumin level to be independent predictors of
persistent diarrhoea or death in the ﬁrst 12 days [40].
Recently Miller et al. [36] analysed the same two clinical
therapeutic trials to derive and validate a categorization system
to discriminate among CDI patients and correlate the grouping
with treatment response. They concluded that a combination
of ﬁve clinical and laboratory variables measured at the time of
CDI diagnosis, combined into a scoring system, were able to
accurately predict treatment response to CDI therapy with
ﬁdaxomicin and vancomycin. These variables include: age,
treatment with systemic antibiotics, leucocyte count, albumin
and temperature (ATLAS).
Strain type has been suggested as an additional cause of
excess morbidity, disease severity and higher recurrence rates
of CDI. In a Canadian study [47], PCR ribotype 027 was
correlated with more severe disease and fatal outcome among
patients at almost all ages. Some studies on the other hand
suggested that PCR ribotype 027 strains might only be
associated with worse outcome in settings where 027 strains
are epidemic, and not in an endemic situation [38,48].
However, these ﬁndings are questioned by others [49].
Recently, a large study by Walker et al. clearly showed that
strain types varied in the overall impact on mortality and
biomarkers (predominantly those associated with inﬂamma-
tory pathways) [50]. Besides C. difﬁcile PCR ribotype 027,
other strains are also associated with outbreaks and severe
C. difﬁcile infection, e.g. PCR ribotype 078 [51]. Despite
increased virulence of speciﬁc strain types, the value of the
PCR ribotype as a prediction marker for disease severity may
be limited, as the ribotype involved in an infection is commonly
not known upon diagnosis. However, in an epidemic situation
the PCR ribotype may be taken into account in deciding on the
choice of empirical treatment regimens [21,39].
The level of host immune response to C. difﬁcile exposure has
been shown to be an important determinant of the severity and
duration of clinical manifestations [52–57]. Anti-toxin antibody
levels have been demonstrated to be higher in healthy adult
controls compared with healthy children, and levels were found
to fall with increasing age. In addition, anti-toxin antibodies
increased after resolution of diarrhoea, which coincided with
decreased incidence of CDI recurrence [57]. Inability to mount
an adequate humoral immune response (e.g. during use of
rituximab) may therefore be an important additional prediction
marker for severe and/or recurrent CDI [25,57–62]. Unfortu-
nately, in most cases this information is not available at
presentation/diagnosis; also, as the strength of evidence for
immunodeﬁciency as an independent predictor for severe and/
or recurrent CDI is still limited, we did not include this risk
factor as a separate prediction marker.
The results from individual studies, reviews and meta-analy-
ses on prognostic markers for CDI were evaluated to reach a
group consensus on a selection of markers that may be useful
in clinical practice to distinguish patients with increased risk for
severe or life-threatening CDI and recurrences. For detailed
recommendations we refer to Tables 5 and 6.
Recommendations. Clostridium difﬁcile infection is judged to be
severe when one or more of the clinical markers of severe
TABLE 4. Patient characteristics that could reasonably be
assumed to correlate positively with severity of colitis in the
absence of another explanation for these ﬁndings
Category Signs/symptoms
Physical examination Fever (core body temperature >38.5°C).
Rigors (uncontrollable shaking and a feeling of
cold followed by a rise in body temperature).
Haemodynamic instability including signs of
distributive shock.
Respiratory failure requiring mechanical
ventilation.
Signs and symptoms of peritonitis.
Signs and symptoms of colonic ileus.
Admixture of blood with stools is rare in
Clostridium difﬁcile infection (CDI) and the
correlation with severity of disease is uncertain.
Laboratory investigations Marked leucocytosis (leucocyte count >159 109/L).
Marked left shift (band neutrophils >20% of
leucocytes).
Rise in serum creatinine (>50% above the
baseline).
Elevated serum lactate (≥5 mM).
Markedly reduced serum albumin (<30 g/L).
Colonoscopy or
sigmoidoscopy
Pseudomembranous colitis.
There is insufﬁcient knowledge on the
correlation of endoscopic ﬁndings compatible
with CDI, such as oedema, erythema, friability
and ulceration, and the severity of disease.
Imaging Distension of large intestine (>6 cm in
transverse width of colon).
Colonic wall thickening including low-
attenuation mural thickening.
Pericolonic fat stranding.
Ascites not explained by other causes.
The correlation of haustral or mucosal
thickening, including thumbprinting,
pseudopolyps and plaques, with severity of
disease is unclear.
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colitis mentioned in Table 4 is present, and/or when one or
more unfavourable prognostic factors (Table 5) is present:
1. Marked leucocytosis (leucocyte count >15 9 109/L)
2. Decreased blood albumin (<30 g/L)
3. Rise in serum creatinine level (≥133 lM or ≥1.5 times the
premorbid level)
Clostridium difﬁcile infection without signs of severe colitis in
older patients (≥65 years), serious comorbidity, ICU admis-
sion, or immunodeﬁciency may also be regarded as increased
risks of developing severe CDI.
Treatment of Clostridium difﬁcile Infection
Once CDI is diagnosed in a patient, immediate implementation
of appropriate infection control measures is mandatory to
prevent further spread within the hospital. These include early
diagnosis of CDI, surveillance, education of staff, appropriate
use of isolation precautions, hand hygiene, protective clothing,
environmental cleaning and cleaning of medical equipment,
good antibiotic stewardship, and speciﬁc measures during
outbreaks. Measures for the prevention and control of CDI
(‘bundle approach’) have been described in an ESCMID
guideline by Vonberg et al. [73].
Additional treatment measures include [1,3,4,72,74]:
 Discontinuation of unnecessary antimicrobial therapy
 Adequate replacement of ﬂuid and electrolytes
 Avoidance of anti-motility medications
 Reviewing proton pump inhibitor use
In general it is difﬁcult to compare studies on the treatment
of CDI because of the use of variable diagnostic criteria,
patient selection and subgroup deﬁnitions, stringency of
searches for potential enteropathogens, severity of CDI,
comorbidities, exposures to causative or concomitant antibi-
otics, and follow up. Moreover, studies have employed
different deﬁnitions of clinical and/or microbiological cure
and recurrence [2,75]. The variability in deﬁnitions and criteria
of randomized controlled trials of antibiotic therapy for CDI is
illustrated in Table 7. In 13/17 randomized controlled trials of
antibiotic treatment of initial CDI, recurrences and duration of
follow up were deﬁned. Follow up varied from 3 to 6 weeks
TABLE 5. Prognostic markers that can be used to determine (increased risk of developing) severe Clostridium difﬁcile infection
(CDI)
Characteristics SoRa QoE Ref (s) Comment(s)
Age (≥65 years) A IIr [32,41,46] Large cohort study on CDI mortality at 30 days, and review of studies of
factors associated with CDI outcome [41]. Systematic review of studies
describing the derivation or validation of Clinical Prediction Rules for
unfavourable outcomes of CDI [46]: in general methodological biases and
weak validities.
Marked leucocytosis (leucocyte count > 15 9 109/L) A IIrht [32,37,39,45,46,63,64] Systematic review [46]: in general methodological biases and weak validities.
Cohort study: severity score on malignancy, white blood cell count, blood
albumin, and creatinine [37]. Retrospective cohort study on risk factors for
severe CDI: death <30 days, ICU, colectomy or intestinal perforation [32].
Decreased blood albumin (<30 g/L) A IIr [32,37,40,46,65] Systematic review [46]: in general methodological biases and weak validities.
Rise in serum creatinine level (≥133 lM or ≥1.5
times the premorbid level)
A IIht [32,37,41,45] Depending on the timing of measurement around CDI diagnosis [45].
Comorbidity (severe underlying disease and/or
immunodeﬁciency)
B IIht [37,41,63,66] Comorbidity: wide variety of risk factors described/investigated, including
cancer, cognitive impairment, cardiovascular, respiratory and kidney disease
[41]. Chronic pulmonary disease, chronic renal disease and diabetes mellitus
[66]. History of malignancy [37]. Previous operative therapy, inﬂammatory
bowel disease and intravenous immunoglobulin treatment [63].
aSoR: degree of recommendation to use a (clinical) characteristic as a prognostic marker.
TABLE 6. Prognostic markers that can be used to determine (increased risk of) recurrent Clostridium difﬁcile infection (CDI)
Characteristics SoRa QoE Ref (s) not exhaustive Comment(s)
Age (>65 years) A IIrh [42,43,46,67] Meta-analysis: [43].
Systematic review: [46].
Prospective validation study of risk factor: [42].
Continued use of (non-CDI) antibiotics after diagnosis of CDI
and/or after CDI treatment
A IIrh [42,43] Meta-analysis: [43].
Prospective validation study of risk factor: [42].
Comorbidity (severe underlying disease) and/or renal failure A IIh [42,45,68] Prospective validation study of risk factor: comorbidity conditions
rated by Horns’ index (scoring system for underlying disease
severity) [42].
A history of previous CDI (more than one recurrence) A IIt [26,40,69–71] Data from randomized controlled trials: [26,70].
Meta-analysis of pivotal randomized controlled trials [40].
Concomitant use of antacid medications (proton pump
inhibitors)
B IIrh [43,72] Meta-analysis on recurrent CDI: [43].
Meta-analysis on CDI: [72].
Initial disease severity B IIth [42,67] Prospective validation study of risk factor [42].
Long-term population based cohort study [67].
aSoR: degree of recommendation to use a (clinical) characteristic as a prognostic marker.
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after treatment for CDI. In 6/17 randomized controlled trials
deﬁnitions for severity of disease were given. In most of the
studies very severe and/or life-threatening CDI was excluded.
A Cochrane analysis published in 2011 reviewed 15 studies
on the antibiotic treatment for CDI in adults [2]. The risk of
bias was rated high in 12 of the 15 included studies. The
authors concluded that a speciﬁc recommendation for the
antibiotic treatment of CDI could not be made. Nevertheless,
and in spite of the observed limitations, it is apparent that a
clear and up-to-date guideline on the treatment of CDI is
urgently needed for clinical practice. For this purpose the
strength of a recommendation and the quality of evidence are
assigned in two separate evaluations in this guideline,
hence allowing an assessment of the strength of a recommen-
dation independent of the level of supportive evidence
(Tables 1 and 2).
To improve clinical guidance in the treatment of CDI,
treatment recommendations are speciﬁed for various patient
groups:
A. Initial CDI: non-severe disease
B. Severe CDI
C. First recurrence or (risk of) recurrent CDI
D. Multiple recurrent CDI
E. Treatment of CDI when oral administration is not
possible
The following treatment options are considered:
1. Oral and non-oral antibiotics
2. Toxin-binding resins and polymers
3. Immunotherapy
4. Probiotics
5. Faecal or bacterial intestinal transplantation
TABLE 7. Randomized controlled trials of antibiotic treatment of initial Clostridium difﬁcile infection (CDI): deﬁnitions and
criteria of recurrences, follow up and severity of infection
Trial
Recurrences before
study
Relapse/recurrences
and follow up Severity of CDI
Severe CDI
excluded/included
[76] Previous PMC excluded Recurrences not deﬁned and follow up
not speciﬁed
Not deﬁned Not speciﬁed
[77] Not described Reappearance of diarrhoea <21 days Not deﬁned Not speciﬁed
[78] Not described Reappearance of diarrhoea <5 weeks Not deﬁned Not speciﬁed
[79] Not described Reappearance of diarrhoea after therapy
Follow up: length not clear
Not deﬁned Not speciﬁed
[80] Not described ‘Recurrence of disease’: not further
speciﬁed
Follow up not deﬁned
No deﬁnition but judged
by physician
Severe/moderate CDI included, mild
CDI excluded
[81] Not described Not described
No follow-up period
Not deﬁned Not speciﬁed
[82] Not described Reappearance of diarrhoea and other
symptoms ≥1 month
Follow up not further speciﬁed
Not deﬁned Not speciﬁed
[83] Treatment for CDI <6 weeks excluded Cure followed by return of inclusion
criteria CDI <4 weeks
Not deﬁned Not speciﬁed
[84] Not described Reappearance of diarrhoea and other
symptoms <25–30 days
Severity estimated by:
number/shape stool, CRP,
WBC, ESR
Severe and mild CDI included. Results
for PMC speciﬁed
[85] CDI ≤6 months excluded Reappearance of diarrhoea during 28–
33 days
Not deﬁned Not speciﬁed. Severe ‘medical
conditions’ excluded
[86] Not speciﬁed
Excluded oral vanco/metro treatment
<7 days before study (at least two
doses included)
Reappearance of symptoms <31
days after start of treatment and
after at least one negative CD
toxin test before retreatment
Not deﬁned Toxic megacolon excluded
[87] Previous CDI excluded Recurrence of diarrhoea during 30 days Not deﬁned Not speciﬁed. Ileus and toxic
megacolon excluded
[88] Prior failure of treatment for CDI with
study drugs excluded
Recurrence of CD toxin-positive
diarrhoea within 21 days
Severe CDI deﬁned as severity
assessment score ≥2 (points).
Based on: age (1), temperature
(1), Alb (1), WBC (1),
endoscopic PMC (2), ICU (2)
Severe and mild CDI included: results
speciﬁed
Life-threatening abdominal
complications excluded
[89] More than one recurrence or relapse
within 3 months before study excluded
Recurrence of CD toxin-positive
diarrhoea <6 weeks
Severity CDI based on:
stools/day, vomiting, ileus,
severe abdominal tenderness,
WBC, toxic megacolon,
life-threatening CDI
Mild to moderately severe CDI
included: results not speciﬁed
Very severe CDI excluded
[90] More than one recurrence <3 months
before study excluded
Results speciﬁed for CDI <90 days
before study.
Return of symptoms (toxin-positive
diarrhoea) <31 days after onset of
treatment, or clinical response
after empiric re-treatment
Severe CDI deﬁned as severity
assessment score ≥2 (points).
Based on: age (1), stools/day (1),
temperature (1), Alb (1), WBC (1)
Severe and mild CDI included: results
speciﬁed
Unstable vital signs or ICU excluded.
[70] More than one CDI <3 months before
study excluded. Results speciﬁed for
patients with/without CDI <3 months
before study.
Reappearance of CD toxin-positive
diarrhoea <4 weeks and need for
retreatment for CDI
Mild, moderate and severe CDI:
based on bowel movements/day,
WBC
Mild, moderate and severe disease
included: results speciﬁed. Life-
threatening or fulminant CDI and
toxic megacolon excluded
[91] More than one CDI <3 months before
study excluded
Results speciﬁed for patients with
CDI <3 months before study.
Return of CD toxin-positive
diarrhoea <30 days and need
for retreatment for CDI
Severe and not-severe CDI based on
ESCMID criteria [1]: WBC,
creatinine, temperature
Severe and not-severe disease included:
results speciﬁed for severity. Life-
threatening or fulminant CDI and
toxic megacolon excluded
Alb, serum albumin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; PMC, pseudomembranous colitis; WBC, white blood cell count.
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A. Initial Clostridium difﬁcile Infection :
non-severe Disease
Oral antibiotic therapy for non-severe disease
Evidence. The antibiotics commonly used to treat CDI are oral
metronidazole or oral vancomycin.
Oral metronidazole has been shown to be effective in
inducing a clinical response and has the advantage of low cost
and is assumed to be associated with reduced vancomy-
cin-resistant enterococci (VRE) selection risk. In a pooled
intention-to-treat analysis (treating exclusions, deaths and
relapses as treatment failures) of three randomized controlled
trials comparing symptomatic cure between metronidazole
and vancomycin [77,84,88], no statistically signiﬁcant
differences were found [2,75]. Symptomatic cure was achieved
in 79% of patients who received vancomycin compared with
71% of patients who received metronidazole (three studies;
335 patients; RR 0.91; 95% CI 0.81–1.03, p 0.14) [2]. However,
a recently presented pooled analysis of data from two phase
three randomized controlled trials on the use of tolevamer,
comparing resolution of diarrhoea and abdominal pain (clinical
success) for vancomycin versus metronidazole, showed that
overall metronidazole was inferior to vancomycin [92].
Vancomycin signiﬁcantly improved clinical success (81.1% vs
72.7%; OR 1.681; 95% CI 1.114–2.537; p 0.0134). In addition a
retrospective analysis of case records of hospitalized patients
with CDI showed that the symptomatic response time was
signiﬁcantly (p <0.01) shorter in patients treated with vanco-
mycin (3.0 days, n = 22) compared with those given metro-
nidazole (4.6 days, n = 28) [23]. Oral metronidazole is usually
recommended for treatment of non-severe disease, whereas
oral vancomycin is generally preferred for treatment of severe
infections [1,3–5].
Decreased clinical effectiveness of metronidazole treat-
ment for speciﬁc ribotypes causing CDI, e.g. PCR ribotype
027, has been described [93]. Although changes in antibiotic
resistance and ribotype prevalence have been reported, in
vitro studies indicate that MICs of metronidazole and vanco-
mycin for endemic C. difﬁcile have remained relatively low
over the years. Brazier et al. concluded that the MICs of
metronidazole and vancomycin were not indicative of clinical
failure, but MICs for epidemic ribotypes (027, 106 and 001)
were several dilutions higher [94]. Indeed there is increasing
evidence of the emergence of reduced susceptibility to
metronidazole in some C. difﬁcile strains, with evidence for
clonal spread [95]. Notably, MIC methodology is crucial to
the detection of reduced susceptibility to metronidazole;
E-tests in particular underestimate the MIC [95,96]. There is
also evidence of inferior microbiological efﬁcacy of metroni-
dazole in comparison with vancomycin [21,22]. Although
poor gut concentrations of metronidazole alongside reduced
susceptibility to metronidazole could explain reduced treat-
ment efﬁcacy, treatment failures have not been associated
with decreased susceptibility [95,97,98]. A case–control study
found no signiﬁcant differences in clinical outcome for CDI
cases from which strains with reduced susceptibility to
metronidazole were recovered versus matched (metronida-
zole-susceptible) controls [99]. Response to metronidazole
was generally poor (slow and prone to recurrence) and the
frail elderly patients had a 21% 30-day mortality. However,
much larger study groups are needed to determine the
clinical signiﬁcance of CD isolates with reduced susceptibility
to metronidazole [99].
Orally administered vancomycin is poorly absorbed from
the gastrointestinal tract, and therefore luminal drug levels are
high and orders of magnitude are greater than the suscepti-
bility breakpoint concentration for all strains of C. difﬁcile
tested so far, thereby resulting in a more rapid suppression of
C. difﬁcile to undetectable levels during therapy and faster
resolution of diarrhoea [22,23]. Metronidazole, on the other
hand, is well absorbed from the gastrointestinal tract. Mean
antibiotic concentrations reported in faeces of patients
receiving oral metronidazole range from <0.25 to 9.5 mg/L,
and drug concentrations in faeces decrease to undetectable
levels as mucosal inﬂammation improves and diarrhoea
resolves [100]. Increased MIC for metronidazole could
therefore have implications on clinical cure or recurrences
in CDI. Although there are no published reports in which
treatment failure has been linked to antimicrobial metronida-
zole resistance in C. difﬁcile, the pharmacokinetic properties of
vancomycin are considered superior to those of metronida-
zole in severe C. difﬁcile disease [88].
There is concern that use of vancomycin may be more likely
to promote colonization and transmission of VRE by selection
pressure. However, both oral metronidazole and oral vanco-
mycin have been associated with the promotion of persistent
overgrowth of VRE in stool samples obtained from colonized
patients during CDI treatment, thereby increasing the risk of
transmission [101]. In a small study of VRE-colonized patients
with CDI, who experienced frequent faecal incontinence, skin
and environmental VRE contamination was common during and
after resolution of diarrhoea. It was concluded that the
frequency of VRE contamination of skin or the environment
was similar between patients treated with metronidazole
(n = 17) and those given vancomycin (n = 17), although the
study clearly had only limited power to examine this issue [102].
In a large retrospective analysis, increased vancomycin use
during an outbreak of CDIwas not associatedwith an increase in
VRE colonization during a follow-up period of 2 years after the
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outbreak period [103]. The authors concluded that restriction
of vancomycin use during CDI outbreaks because of the fear of
increasing VRE colonization might not be warranted. However,
the interpretation of the data was complicated by an outbreak of
VRE (VanA) cases that was observed after approximately
20 months of increasing preferential use of vancomycin. As
the rate of VanA cases subsequently decreased very quickly, the
investigators concluded that this temporary increase reﬂected a
localized clonal outbreak unrelated to the CDI therapy at that
time [103].
Although vancomycin and metronidazole are effective in the
treatment of CDI, they are both broader-spectrum agents that
cause signiﬁcant disruption of the commensal colonic microbi-
ota. A disruption in the commensal microbiota may predispose
to recurrent CDI and intestinal colonization by health-
care-associated pathogens such as VRE and Candida species.
Fidaxomicin appears to cause less disruption of the anaerobic
colonization microbiota, and has activity against many VRE
strains [104] so it is suggested that the risk of colonization with
and transmission of VRE associated with ﬁdaxomicin treatment
may be lower compared with vancomycin therapy. A recent
study concluded that ﬁdaxomicin was indeed less likely than
vancomycin to promote acquisition of VRE and Candida species
during CDI treatment. However, selection of pre-existing
subpopulations of VRE with elevated ﬁdaxomicin MICs was
more common during ﬁdaxomicin therapy [105].
Similar cure rates have been demonstrated for oral
vancomycin and oral teicoplanin [82,84]. For bacteriological
cure, oral teicoplanin may even be more effective than
vancomycin [2,82]. Both glycopeptides are active in vitro
against C. difﬁcile isolates [106]. Since 2013 teicoplanin does
have a licensed indication for CDI and is available for oral
administration. Teicoplanin is not available in the USA. For
the purpose of this treatment guideline only oral vancomycin
is included in the treatment recommendations.
Tables 8 and 9 report the evidence for oral treatment of
initial CDI from randomized trials and observational studies
with comments on methodology.
Although oral metronidazole absorption is very high and
potentially can lead to more systemic side-effects, adverse
effects of oral metronidazole are commonly mild to moder-
ate in severity. The most common adverse reactions
reported involve the gastrointestinal tract [107]. Rarely,
particularly in association with long duration therapy, met-
ronidazole has been linked to more severe safety issues, e.g.
peripheral and optic neuropathy [108] and interactions with
warfarins [109].
Oral vancomycin has been shown to be poorly absorbed in
most patients, usually producing minimal or subtherapeutic
serum concentrations. However, bowel inﬂammation may
enhance absorption of oral vancomycin, particularly in those
with renal failure, thereby increasing the risk for systemic
side-effects [110]. A recently performed safety analysis of
ﬁdaxomicin in comparison with oral vancomycin revealed no
differences in serious adverse events between these agents
[111]. Fidaxomicin is minimally absorbed. While no speciﬁc
concerns related to hypersensitivity reactions were identiﬁed
during the drug development, hypersensitivity reactions
associated with ﬁdaxomicin use have been reported to the
FDA in the post-marketing phase. The ﬁdaxomicin labeling
was revised to include information about the possibility of
hypersensitivity reactions [112].
To evaluate the clinical outcomes of the main antimicrobial
agents used in the treatment of CDI, we compared dosages,
cure rate, recurrence rate, stated time to response and
adverse events of treatment with vancomycin, metronidazole
and ﬁdaxomicin. Only randomized controlled trials of antibi-
otic treatment of initial CDI were included. Results are
summarized in Table 10.
Recommendations. In case of non-severe CDI (no signs of severe
colitis) in non-epidemic situations and with CDI clearly induced by
the use of antibiotics, it may be acceptable to stop the inducing
antibiotic and observe the clinical response for 48 h, but
patients must be followed very closely for any signs of clinical
deterioration and placed on therapy immediately if this occurs.
Metronidazole is recommended as oral antibiotic treatment of
initial CDI in mild/moderate disease. For detailed recommen-
dations on oral antibiotic treatment of initial non-severe CDI
refer to Table 11.
Alternative treatment regimens treatment for non-severe
disease
Evidence. Tables 12 and 13 report the evidence from random-
ized trials and observational studies on the non-antibiotic
treatment of initial CDI, with comments on methodology. The
majority of these alternative treatment strategies are com-
bined with antibiotic treatment.
Currently there are no randomized controlled trials on the
use of human intravenous gammaglobulins (IVIG). Passive
immunizations with IVIG have been reported to be successful
in small case series, but the grade of evidence and strength of
recommendation of IVIG are too weak to allow recommen-
dations on the use of IVIG in CDI [4,130]. Hypogammaglob-
ulinaemia, e.g. following solid organ transplants, may
predispose to CDI. For this subgroup of patients, IVIG may
be beneﬁcial, but more studies are needed before this can be
recommended deﬁnitively [4].
A recent systematic review on the use of probiotics
suggests that probiotics are associated with a reduction in
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antibiotic-associated diarrhoea [131]. A recent meta-analysis
on probiotic prophylaxis for CDI, concluded that moder-
ate-quality evidence suggests a beneﬁcial effect of probiotic
prophylaxis in CDI without an increase in clinically important
adverse events [132]. However, a Cochrane analysis con-
cluded that there was insufﬁcient evidence to recommend
probiotics, in general, as an adjunct to antibiotics in the
treatment of C. difﬁcile diarrhoea [133]. Although no cases of
TABLE 8. Randomized controlled trials of oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI). Initial cure rate
and sustained response rates as a percentage of all patients and relapse rate as a percentage of initially cured patients
Trial Treatment
Number of
patients
Cure
(%)
Recurrence
(%)
Sustained
response (%)
[76] Vancomycin, 125 mg four times daily, 5 days 9 78 0 78
Placebo 7 14 – –
No clear case deﬁnition. No description of allocation of treatment. Only data of patients with toxin-positive stool shown. Unclear length of follow up and incidence
or relapse in placebo group. p <0.02 for comparison of cure rates.
[77] Vancomycin, 500 mg four times daily, 10 days 32 100 19 81
Metronidazole 250 mg four times daily, 10 days 32 97 6 91
Only data of patients with toxin-positive stools or pseudomembranous colitis shown. Per-protocol analysis. Follow up 21 days. Differences not statistically signiﬁcant.
[78] Vancomycin, 125 mg four times daily, 7 days 21 86 33 58
Bacitracin, 20 000 U four times daily, 7 days 21 76 42 44
Double-blind. 25% drop-out during follow up of bacitracin group. Follow up 5 weeks. Differences not statistically signiﬁcant.
[79] Vancomycin, 500 mg four times daily, 10 days 15 100 20 80
Bacitracin, 25 000 U four times daily, 10 days 15 80 42 46
Double-blind. Patients had leucocytosis, fever or abdominal pain. 29% drop-out in vancomycin group, 12% in bacitracin group. Per-protocol analysis. Unclear
deﬁnition of failure (‘worsening during treatment’). Failing patients crossed over to alternate drug. Interruption of study drug in vancomycin group for a mean of
2.8 days and in bacitracin group for a mean of 1.8 days. Unclear length of follow up. Differences not statistically signiﬁcant.
[80] Vancomycin, 125 mg four times daily, mean 10.6 days 24 100 21 79
Vancomycin, 500 mg four times daily, mean 10.1 days 22 100 18 82
Variable duration of therapy. 18% dropout rate. Per-protocol analysis. Unclear length of follow up. Differences not statistically signiﬁcant.
[81] Vancomycin, 500 mg twice daily, 10 days 10 100 – –
Rifaximin, 200 mg three times daily, 10 days 10 90 – –
Article in Italian. Patients had diarrhoea, abdominal pain and fever. No description of allocation of treatment. Unclear deﬁnition of cure. Differences not statistically
signiﬁcant.
[82] Vancomycin, 500 mg four times daily, 10 days 20 100 20 80
Teicoplanin, 100 mg twice daily, 10 days 26 96 8 88
No description of allocation of treatment. Per-protocol analysis. Unclear length of follow up (‘at least 1 month’). Differences not statistically signiﬁcant.
[83] Teicoplanin, 100 mg four times daily, 3 days, followed by 100 mg twice daily, 4 days 24 96 35 62
Teicoplanin, 100 mg twice daily, 7 days 23 70 50 35
Double-blind. Outcome of ‘improvement, but not cure’ (two loose stools per day or one loose stool per day with fever or cramps) was counted as failure. Three
patients with improvement in twice daily group; one in four times daily group. Follow up 5 weeks. p 0.08 for comparison of cure rates.
[84] Vancomycin, 500 mg three times daily, 10 days 31 94 17 78
Metronidazole, 500 mg three times daily, 10 days 31 94 17 78
Teicoplanin, 400 mg twice daily, 10 days 28 96 7 89
Fusidic acid, 500 mg three times daily, 10 days 29 93 30 65
Follow up 30 days. Only statistically signiﬁcant difference was relapse rate of fusidic acid versus teicoplanin (p 0.042).
[85] Metronidazole, 400 mg three times daily, 7 days 55 93 30 65
Fusidic acid, 250 mg three times daily, 7 days 59 83 30 58
Double-blind. 13% drop-out during treatment; 15% further drop-out during follow up. Per-protocol analysis. Follow up 35 days. Differences not statistically
signiﬁcant.
[86] Metronidazole, 250 mg four times daily, 10 days 34 82 30 57
Nitazoxanide, 500 mg twice daily, 7 days 40 90 6 67
Nitazoxanide, 500 mg twice daily, 10 days 36 89 16 75
No deﬁnition of relapse. Double-blind. 23% drop-out during treatment. Per-protocol analysis. Follow up 31 days. Differences not statistically signiﬁcant.
[87] Metronidazole, 500 mg three times daily, 10 days 20 65 38 40
Metronidazole, 500 mg three times daily + rifampicin 300 mg twice daily, 10 days 19 63 42 37
Intention-to-treat analysis. Follow up 40 days. Differences not statistically signiﬁcant.
[88] Vancomycin, 125 mg four times daily, 10 days 71 97 7 90
Metronidazole, 250 mg four times daily, 10 days 79 84 14 72
Double-blind. 13% drop-out during treatment. Per-protocol analysis. Follow up 21 days. p 0.006 for comparison of cure rates. p 0.27 for comparison of relapse
rates. The original protocol was stratiﬁed in a group with mild and a group with severe disease (based on age, fever, albumin level and leucocyte count), which
resulted in a larger difference between cure rates in the group with severe disease and a statistically non-signiﬁcant difference between cure rates in the group with
mild disease. Intention-to-treat analysis with dropouts regarded as failures resulted in a statistically signiﬁcant difference between overall cure rates (initial cure
minus relapse; 57 out of 90 versus 64 out of 82; risk ratio 0.91). Other comparisons were not signiﬁcant anymore in the intention-to-treat analysis.
[89] Fidaxomicin, 50 mg twice daily, 10 days 14 71 8 65
Fidaxomicin, 100 mg twice daily, 10 days 15 80 0 80
Fidaxomicin, 200 mg twice daily, 10 days 16 94 6 88
Open-label. Patients with signs of highly severe CDI (>12 bowel movements per day, vomiting, severe abdominal tenderness, ileus, white blood cell count >30, toxic
megacolon) were excluded. Cure = complete resolution of diarrhoea. Follow up 6 weeks after end of treatment.
[90] Vancomycin, 125 mg four times daily, 10 days 27 74 7 69
Nitazoxanide, 500 mg twice daily, 10 days 22 77 5 73
CDI = stool EIA for toxin A or B positive AND (temperature >38.3°C OR abdominal pain OR leucocytosis). Patients with more than one episode in preceding
6 months were excluded. 12% dropout rate during treatment. Double-blind, placebo-controlled. Modiﬁed intention-to-treat analysis. Industry-sponsored.
Cure = complete resolution of symptoms during 3 days after completion of therapy. Per-protocol analysis: 87 versus 94% cure. Follow up 31 days after start of
treatment. No differences in severity subgroups. Differences not statistically signiﬁcant.
[70] Vancomycin, 125 mg four times daily, 10 days 309 86 25 65
Fidaxomicin, 200 mg twice daily, 10 days 287 88 15 75
Placebo-controlled. Industry-sponsored. Very severe CDI and more than one previous episode excluded. Designed as non-inferiority trial. 4 weeks follow up for
recurrences after completion of study drug. Cure = <4 times daily passage of unformed stools AND no necessity for additional treatment. Fidaxomicin was not
associated with fewer recurrences in CDI due to PCR ribotype 027 as opposed to non-027. Modiﬁed intention-to-treat (patients who received at least one dose of
the study drug) and per-protocol analyses were similar.
[91] Vancomycin, 125 mg four times daily, 10 days 257 87 27 64
Fidaxomicin, 200 mg twice daily, 10 days 252 88 13 77
Methods identical to the trial by Louie et al. [70]. Contrary to that trial, this trial did show fewer recurrences in both polymerase chain reaction ribotype 027 and
non-027 patients, although the difference was not signiﬁcant for the former subgroup.
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translocation of microorganisms have been reported in clinical
trials with probiotics for antibiotic-associated diarrhoea or
CDI, probiotics should be used with caution. Several studies of
invasive disease have been reported, resulting from the use of
probiotics such as Saccharomyces boulardii in debilitated or
immunocompromised patients [134,135]. Moreover, probiot-
ics were associated with increased mortality, partly due to
non-occlusive mesenteric ischaemia, in a randomized
controlled trial in acute pancreatitis [136].
Recommendations. There is insufﬁcient evidence to support
administration of probiotics, toxin-binding resins and poly-
mers, or monoclonal antibodies. For detailed recommenda-
tions refer to Table 14.
B: Severe Clostridium difﬁcile Infection
Oral antibiotic therapy
Evidence. In 6/17 randomized controlled trials, severity of
disease was deﬁned. Deﬁnitions varied among the studies.
Only in 4/6 of these trials were treatment results speciﬁed for
severity of disease (Table 15).
Recommendations. Based on its pharmacokinetic properties
vancomycin is considered superior to metronidazole in severe
C. difﬁcile disease [22,88]. The use of high doses of vancomy-
cin (500 mg orally four times daily) was included in the
Infectious Diseases Society of America/Society for Healthcare
Epidemiology of America treatment guidelines [3] for man-
agement of severe complicated CDI as deﬁned by the treating
physician. However, there is insufﬁcient evidence to support
the use of doses >125 mg four times daily in the absence of
ileus [80].
Fidaxomicin was not inferior to vancomycin for initial cure
of CDI, but there are no data available on the efﬁcacy of this
drug in severe life-threatening disease [70,91].
For detailed recommendations on oral antibiotic treatment
of severe CDI refer to Table 16.
Surgery for complicated Clostridium difﬁcile infection
Evidence. Patients with fulminant CDI who fail to respond and
who progress to systemic toxicity, peritonitis, or toxic colonic
dilatation and bowel perforation require surgical intervention
[4]. Mortality rates of emergency surgery in complicated CDI
remain high, ranging from 19% to 71% depending on the clinical
condition of the patient at the time of surgery [138]. However,
recently a systemic review of the existing literature was
performed to assess the effect on mortality of colectomy for
the treatment of fulminant CDI. The authors concluded that
colectomy is associated with a lower mortality than continued
medical treatment when this is no longer improving the patient
[139]. Several studies suggest that earlier colectomy (time
from presentation to surgery) is associated with improved
survival [140]. Independent risk factors for mortality in
patients who underwent colectomy that have been found
among multiple studies include: the development of shock
(need for vasopressors), increased serum lactate (≥5 mM),
mental status changes, end organ failure, renal failure and the
need for preoperative intubation and ventilation
[29,35,138,141,142]. The more negative prognostic signs a
patient has, the earlier surgical consultation and operative
management should be considered. The established operative
management of severe, complicated CDI has been subtotal
colectomy with end-ileostomy [140]. However, recently an
alternative surgical treatment with creation of a diverting loop
ileostomy, followed by colonic lavage, has been shown to
reduce morbidity and mortality, while preserving the colon.
The surgical approach involves the laparoscopic creation of a
diverting loop ileostomy. The colon is then lavaged in an
ante-grade fashion through the ileostomy with a high volume
TABLE 9. Observational studies of oral antibiotic treatment
of initial Clostridium difﬁcile infection (CDI). Initial cure rate
and sustained response as a percentage of all patients and
relapse rate as a percentage of initially cured patients
Trial Treatment
Number
of patients
Cure
(%)
Recurrence
(%)
Sustained
response
(%)
Antibiotics
[113] Vancomycin 79 96 14 83
[114] Vancomycin 16 100 13 87
[115] Metronidazole 13 100 15 85
[116] Vancomycin 189 97 24 74
[106] Vancomycin 500
mg four times daily,
10 days
23 100 13 87
Teicoplanin 200 mg
twice daily, 10 days
22 100 0 100
[117] Metronidazole 632 98 6 92
Vancomycin 122 99 10 89
[57] Metronidazole 44 ? 50 –
[118] Metronidazole 99 62 ? –
[119] Metronidazole 207 78 28 56
[68] Metronidazole 1123 84 29 60
Vancomycin 112 ? 28 -
[120] Fidaxomicin varying
dose
45 91 5 86
[121] Nitazoxanide 500
mg twice daily,
10 days
35 74 27 54
Patients ﬁrst failed
metronidazole
[101] Metronidazole 34 >90 12 >79
Ten patients
switched
to vancomycin
Vancomcyin 18 >90 11 >80
[122] Tigecycline varying
duration
4 100 0 100
Severe CDI. Follow
up at least 3
months
[123] Rifaximin 400 mg
three times daily
8 100 10 90
2 weeks follow up
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TABLE 10. Results of randomized controlled trials of oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI) with
vancomycin/teicoplanin, metronidazole and ﬁdaxomicin: comparison of dosages, cure rate, recurrence rate, stated time to
response or adverse effects due to treatment
Trial
Number of
patients
Dosages and
duration of
therapy
Time to initial
response (mean)
Cure rate
(%)
Recurrence rate
(%) and deﬁnition
Adverse events
(%)
Vancomycin [76] 9 125 mg four times
daily 5 days
– 78 0
Recurrence not deﬁned,
follow-up period not
speciﬁed
–
[77] 32 500 mg four times
daily 10 days
3.2 days 100 19
Reappearance of diarrhoea
<21 days after therapy
3
Drug intolerance
[78] 21 125 mg four times
daily 7 days
– 86 33
Reappearance of diarrhoea
<5 weeks after therapy
–
[79] 15 500 mg four times
daily 10 days
– 100 20
Reappearance of diarrhoea
after therapy
Follow-up: length not clear
–
[80] 24 125 mg four times
daily mean 11 days
4 days 100 21 0
22 500 mg four times
daily mean 10 days
4 days 100 18
Recurrence of disease not
further speciﬁed
Follow up not deﬁned
0
[81] 10 500 mg twice
daily 10 days
3.8 days 100 Not described
No follow-up period
0
[82] 20 500 mg four times
daily 10 days
3.6 days 100 4
Reappearance of diarrhoea
and other symptoms ≥1
month after therapy. Follow
up not further speciﬁed
0
[84] 31 500 mg three times
daily 10 days
3.1 days 94 17
Reappearance of diarrhoea
and other symptoms
<25–30 days after therapy
0
[88] 71 125 mg four times
daily 10 days
– 97 7
Recurrence of CD toxin-
positive diarrhoea within 21
days after start of therapy
1 (nausea)
[90] 27 125 four times
daily 10 days
Median: 96 h 74 7
Return of symptoms (toxin-
positive diarrhoea) <31
days after onset of
treatment, or clinical
response after empiric
re-treatment for CDI
0
[70] 30 125 mg four times
daily 10 days
Median: 78 h 86 25
Reappearance of CD toxin-
positive diarrhoea <4
weeks after treatment and
need for retreatment for
CDI
Possibly or deﬁnitely
related: nine serious events related to
laboratory test results: 1.2
[91] 257 125 mg four times
daily 10 days
Median: 58 h 87 27
Return of CD toxin positive
diarrhoea <30 days after
treatment and need for
retreatment for CDI
Any treatment-emergent adverse event
related to study drug: 13.8
Teicoplanin [82] 26 100 mg twice
daily 10 days
3.4 days 96 2
Reappearance of diarrhoea
and other symptoms ≥ 1
month after therapy. Follow
up not further speciﬁed
0
[84] 28 400 mg twice
daily 10 days
2.8 days 96 7
Reappearance of diarrhoea
and other symptoms
< 25–30 days after therapy
0
[83] 24 100 mg four times
daily, 3 days,
followed by 100
mg twice daily,
4 days
– 96 35 7–8
vomiting, nausea, exanthema, arthralgia,
pruritus, hallucinations. No abnormal
laboratory results
23 100 mg twice
daily 7 days
70 50
Metronidazole [77] 32 250 mg four times
daily 10 days
3.1 days 97 6
Reappearance of diarrhoea
<21 days after therapy
3
[84] 31 500 mg three times
daily 10 days
3.2 days 94 17
Reappearance of diarrhoea
and other symptoms
<25–30 days after therapy
10
Gastrointestinal discomfort
[85] 55 400 mg three times
daily 7 days
Within 5 days 93 30
Reappearance diarrhoea
14.5
Gastrointestinal discomfort,
exanthema, taste
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of polyethylene glycol 3350 or balanced electrolyte solution
and the efﬂuent is collected via a rectal drainage tube. A
catheter is placed in the efferent limb of the ileostomy to
deliver vancomycin ﬂushes in an antegrade fashion in the
postoperative period. In addition, patients receive intravenous
metronidazole for 10 days [143]. A multicentre randomized
controlled trial is currently being conducted to provide level I
evidence for possible implementation of this new treatment
into standard practice [http://clinicaltrials.gov/show/
NCT01441271].
Recommendations. Total abdominal colectomy should be
performed to treat CDI in case of:
 Perforation of the colon
 Systemic inﬂammation and deteriorating clinical condition
despite maximal antibiotic therapy; this includes the clinical
diagnoses of toxic megacolon, acute abdomen and severe
ileus. Colectomy should preferably be performed before
colitis becomes very severe. Serum lactate may, inter alia,
serve as a marker for severity (operate before lactate
exceeds 5.0 mM).
A future alternative to colectomy may be diverting loop
ileostomy and colonic lavage, combined with antibiotic treat-
ment (intracolonic antegrade vancomycin and intravenous
metronidazole).
Table 10 (Continued)
Trial
Number of
patients
Dosages and
duration of
therapy
Time to initial
response (mean)
Cure rate
(%)
Recurrence rate
(%) and deﬁnition
Adverse events
(%)
during 28–33 days after
treatment
[86] 34 250 mg twice
daily 10 days
Median: 3 days 82 30
Reappearance of symptoms
<31 days after start of
treatment and after at least
one negative CD toxin test
before retreatment
Related to study drug: 0 serious adverse
events not related to study drug:18.2
intolerance or allergy:0
[87] 20 500 mg three times
daily 10 days
6.6 days 65 38
Recurrence of diarrhoea
<30 days after treatment
40 (not speciﬁed if related to study
drug: rash, nausea vomiting)
[88] 79 250 mg four times
daily 10 days
– 84 14
Recurrence of CD toxin-
positive diarrhoea <21 days
after start of therapy
1.3 (nausea)
Fidaxomicin [89] 14 50 mg twice
daily 10 days
Median 6.3 days 71 8 20 but not related to study drug
15 100 mg twice
daily 10 days
Median 4.8 days 80 0
16 200 mg twice
daily 10 days
Median 3.6 days 94 6
Recurrence of CD toxin-
positive diarrhoea <6 weeks
after treatment
[70] 287 200 mg twice
daily 10 days
Median 58 h in the
MITT
88 15
Reappearance of CD toxin-
positive diarrhoea <4 weeks
and need for retreatment
for CDI
Possibly or deﬁnitely related: 9.7
Serious events related to laboratory
test results: 4.7
[91] 252 200 mg twice
daily 10 days
Median 56 h 88 13
Return of CD toxin-positive
diarrhoea <30 days and
need for retreatment for
CDI
Any treatment-emergent adverse event
related to study drug: 11.7
TABLE 11. Recommendations on oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI): non-severe disease
Treatment SoR QoE Ref(s) Comment(s)
Metronidazole, 500 mg three
times daily 10 days
A I [77,84–88] No statistically signiﬁcant difference in cure rate between metronidazole and vancomycin or
teicoplanin.
Statistically signiﬁcant difference in sustained clinical cure between metronidazole and
vancomycin in favour of vancomycin in one study [2,88] (and pooled results of two
randomized controlled trials published only in abstract form [92,123,124]).
Vancomycin, 125 mg four
times daily 10 days
B I [70,76,78,80,82,84,88,90,91] Cochrane analysis: teicoplanin signiﬁcantly better than vancomycin for bacteriological cure and
borderline superior in terms of symptomatic cure [2].
Fidaxomicin, 200 mg twice
daily 10 days
B I [70,89,91] Evidence limited to two Phase III studies. Fewer recurrences as compared to vancomycin,
except for C. difﬁcile PCR ribotype 027 [91].
Vancomycin, 500 mg four
times daily 10 days
C I [77,79–82,84] Vancomycin: Equal cure rate 500 mg four times daily orally compared with 125 mg four times
daily orally [80].
Stop inducing antibiotic(s)
and observe the clinical
response for 48 h
C II [116,117] Rate of spontaneous resolution unknown in mild CDI.
Studies performed before increased incidence of hypervirulent strains.
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C: First Recurrence or (Risk of) recurrent
Clostridium difﬁcile Infection
Oral antibiotic therapy
Evidence. In 3/17 randomized controlled trials of antibiotic
treatment of initial CDI, results were speciﬁed for CDI before
the study (Table 17).
Recommendations. The incidence of a second recurrence
after treatment of a ﬁrst recurrence with oral metronida-
zole or vancomycin is similar. Fewer secondary recurrences
with oral ﬁdaxomicin as compared with vancomycin after
treatment of a ﬁrst recurrence are reported [70,91,144].
However, the evidence on ﬁdaxomicin for this speciﬁc
subgroup of CDI patients is limited to two phase III studies
and based on a retrospective subset analysis of data and a
limited number of patients (number of patients in the
modiﬁed intention-to-treat analysis: ﬁdaxomicin n = 79 and
vancomycin n = 80) [144]. There are no prospective
randomized controlled trials performed with metronidazole,
vancomycin or ﬁdaxomicin in this speciﬁc patient group. In
addition, ﬁdaxomicin was not associated with fewer recur-
TABLE 12. Randomized controlled trials of alternative treatment regimens for initial Clostridium difﬁcile infection (CDI). Initial
cure rate and sustained response as a percentage of all patients and relapse rate as a percentage of initially cured patients
Trial Treatment
Number of
patients
Cure
(%)
Recurrence
(%)
Sustained
response (%)
Probiotics
[126] Vancomycin or metronidazole + Saccharomyces
boulardii 2 9 1010 CFU/day, 4 weeks
31 – 19 –
Vancomycin or metronidazole + placebo 33 – 24 –
Double-blind. No control for type, duration or dose of antibiotic. Unclear deﬁnition of relapse. Follow up 8 weeks after start of treatment. p 0.86 for
comparison of relapse rates.
Toxin-binding resins and polymers:
[24] Tolevamer 1 g three times daily, 14 days + placebo 94 60 16 50
Tolevamer 2 g three times daily, 14 days + placebo 91 79 7 74
Vancomycin 125 mg four times daily, 10 days + placebo 94 91 19 74
Non-inferiority trial. Patients with stool frequency >12 daily or abdominal pain were excluded. Tolevamer could be prolonged when inciting antibiotic could
not be stopped. Double-blind. 23% drop-out. Per-protocol analysis. Cure rate of tolevamer 2 g non-inferior in comparison with vancomycin (Chow-test
p 0.03). Non-inferiority of tolevamer 1 g compared with vancomycin could not be demonstrated. p 0.05 for comparison of relapse rates of tolevamer 2 g
with vancomycin. Relapse rates of tolevamer 1 g and vancomycin not statistically different. Follow up 6–8 weeks.
[124]a Tolevamer, 3 g three times daily, 14 days 266 47 3 46
Vancomycin, 125 mg four times daily, 10 days 134 81 23 62
Metronidazole, 375 mg four times daily, 10 days 143 72 27 53
[125]a Tolevamer, 3 g three times daily, 14 days 268 42 6 40
Vancomycin, 125 mg four times daily, 10 days 125 81 18 66
Metronidazole, 375 mg four times daily, 10 days 135 73 19 59
Immunotherapy
[71] Single dose of 10 mg/kg CDA1 and CDB1
(intravenously administered human monoclonal
antibodies against TcdA and TcdB) with
standard antimicrobial therapy
101 93 7 87
Placebo with standard antimicrobial therapy 99 87 25 65
Industry-sponsored and -analysed. Patients must have diarrhoea and receive vancomycin or metronidazole at time of enrolment. Diarrhoea at least two
unformed stools on two consecutive days or more than six unformed stools on 1 day. Recurrence = new episode of diarrhoea with new positive stool
toxin test after resolution of initial diarrhoea. Analysis for recurrence only performed in those who were cured, received >7 days of antimicrobial therapy
and did not receive intravenous immunoglobulin (93 versus 82). Dropout rate 9 versus 13%, mainly due to deaths not related to CDI. Only 30% (n = 30) of
patients treated with vancomycin received monoclonal antibodies versus 22% (n = 22) placebo. Follow up 12 weeks. p <0.001 for comparison of relapse
rates. Intention-to-treat analysis. Primary endpoint was changed during the study before unblinding. Original endpoint: resolution of illness. Subgroup
analysis: similar results, although difference much smaller in inpatients than outpatients. Length of hospitalization did not differ.
aPoster presentation.
TABLE 13. Observational studies of alternative treatment regimens for initial Clostridium difﬁcile infection (CDI). Initial cure rate
as a percentage of all patients and relapse rate as a percentage of initially cured patients
Trial Treatment
Number of
patients
Cure
(%)
Recurrence
(%)
Toxin-binding resins and polymers
[127] Colestipol 10 g four times daily, 5 days 12 25 –
Originally set up as a randomized placebo-controlled trial. Placebo group was merged with historical control, however. Only six patients had toxin-positive
stool.
Passive immunotherapy with immune whey:
[128] Metronidazole or vancomycin followed by immune whey protein concentrate, 14 days 16 100 0
56% of patients had recurrent CDI; mean follow up 333 days.
[129] Metronidazole or vancomycin followed by immune whey protein concentrate, 14 days 109 100 10
109 episodes; 101 patients; 40% of patients had recurrent CDI.
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rences in CDI due to PCR ribotype 027 as opposed to
non-027 in one of the randomized controlled trials [70].
Therefore, based on the evidence currently available, the
Strength of Recommendation for treating a ﬁrst recurrence
of CDI with oral vancomycin or oral ﬁdaxomicin is
considered equal (B-I), unless disease has progressed from
non-severe to severe.
For detailed recommendations on oral antibiotic treatment
of mild/moderate initial CDI with risk for recurrent CDI or a
ﬁrst recurrence refer to Table 18.
TABLE 15. Randomized controlled trials of oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI) in which
severity of disease is deﬁned and outcome of treatment is speciﬁed for severity of diseases
Study Treatment
CDI severity:
moderate/mild
(M), severe (S)
Nr of patients (%)
Initial cure
No. of patients
(%)
Relapse
No. of patients
(% of patients
with initial cure)
Sustained response
ratea
No. of patients (% of all
patients)
[88] Vancomycin, 125 mg four
times daily, 10 days
M 40/71 (56)
S 31/71 (44)
39/40 (98)
30/31 (97)
2/39 (5)
3/30 (10)
37/40 (93)
27/31 (87)
Metronidazole 250 mg four
times daily, 10 days
M 41/79 (52)
S 38/79 (48)
37/41 (90)
29/38 (76)
3/37 (8)
6/29 (21)
34/41 (83)
23/38 (61)
Intention-to-treat analysis:
Vancomycin 125 mg four
times daily, 10 days
M 44/82 (49)
S 38/82 (46)
39/44 (89)
30/38 (79)
2/39 (5)
3/30 (10)
37/44 (84)
27/38 (71)
Metronidazole 250 mg four
times daily, 10 days
M 46/90 (51)
S 44/90 (49)
37/46 (80)
29/44 (66)
3/37 (8)
6/29 (21)
34/46 (74)
23/44 (52)
[90] Vancomycin, 125 mg four
times daily, 10 days
M 17/27 (63)
S 10/27 (37)
13/17 (76)
7/10 (70)
1/13 (8)
1/7 (14)
12/17 (71)
6/10 (60)
Nitazoxanide 500 mg
twice daily, 10 days
M 12/22 (55)
S 10/22 (45)
9/12 (75)
8/10 (80)
0/9 (0)
1/8 (13)
9/12 (75)
7/10 (70)
[70] Vancomycin 125 mg four
times daily, 10 days
M 186/309 (60)
S 123/309 (40)
156/186 (85)
109/123 (89)
38/156 (24)
29/109 (27)
118/186 (63)
80/123 (65)
Fidaxomicin 200 mg twice
daily, 10 days
M 175/287 (61)
S 112/287 (39)
161/175 (92)
92/112 (82)
27/161 (17)
12/92 (13)
134/175 (77)
80/112 (71)
[91] Vancomycin 125 mg four
times daily, 10 days
M 196/257 (76)
S 61/257 (24)
180/196 (92)
43/61 (71)
46/180 (26)
14/43 (33)
134/196 (68)
29/61 (48)
Fidaxomicin 200 mg twice
daily, 10 days
M 189/252 (75)
S 63/252 (25)
173/189 (92)
48/63 (76)
24/173 (14)
4/48 (8)
149/189 (79)
44/63 (70)
aSustained response rate: clinical cure and no recurrences during follow up.
TABLE 14. Recommendations on alternative treatment regimens for initial Clostridium difﬁcile infection (CDI)
Type of intervention Treatment SoR QoE Ref(s) Comment(s)
Immunotherapy Human monoclonal antibodies
against TcdA and TcdB with
standard oral antimicrobial
therapy (metronidazole and
vancomycin)
C I [71] Evidence limited to Phase II randomized controlled trial.
Primary endpoint changed during study.
Reduced recurrence of CDI: analysis for recurrence only performed
in those who were cured, received >7 days of antimicrobial therapy and
did not receive intravenous gammaglobulins
Passive immunotherapy with
immune whey after standard
oral antimicrobial therapy
C II [129] Observational study: 101 CDI patients (40% recurrent CDI).
Results suggest reduction in recurrence rate.
Probiotics Oral vancomycin or oral
metronidazole +
Saccharomyces boulardii
D I [126,137] Comparison of relapse rates: in subgroup analysis efﬁcacy in recurrent CDI,
but not in initial CDI.
Evidence-based review: [137].
Toxin-binding resins and polymers Tolevamer, 3 g three times
daily
D I [24] Evidence limited to Phase II randomized controlled trial. Non-inferiority
study: tolevamer versus vancomycin.
TABLE 16. Recommendations on oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI): severe disease
Treatment SoR QoE Ref(s) Comment(s)
Vancomycin, 125 mg four
times daily for 10 days
A I [70, 88, 90, 91] Cure rate higher as compared with metronidazole in severe CDI [88]a
Vancomycin 500 mg four
times daily for 10 days
B III (Ia) [80] Randomized controlled trial on dose effectiveness: no signiﬁcant differences in measurable responses of
high-dose compared to low-dose regimens. However: results not stratiﬁed for severity of illness [80]a.
Fidaxomicin 200 mg twice
daily for 10 days
B I [70,89,91] Evidence limited to two Phase III studies [70,91].
Fewer recurrences compared with vancomycin 125 mg four times daily in severe disease (except for PCR
ribotype 027). No data on the efﬁcacy in severe life-threatening disease and/or toxic megacolon: excluded
from both studies.
Metronidazole, 500 mg
three times daily for 10
days
D I [88] Cure rate lower as compared with vancomycin in severe CDI [88]. Intention to treat analysis not reported.
Extremely severe CDI excludeda.
Differences in symptomatic cure of metronidazole versus vancomycin not statistically signiﬁcant in a pooled
analysis [2]. ICU admission and hypoalbuminaemia (= disease severity) predictors of metronidazole failure
[119].
aTwo studies reported in abstract form conﬁrm the superiority of vancomycin over metronidazole for treatment of (severe) CDI [92,124,125].
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D: Multiple recurrent Clostridium difﬁcile
Infection
Antibiotic and non-antibiotic treatment strategies
Evidence. Tables 19 and 20 report the evidence from random-
ized trials and observational studies with comments on
methodology.
Recommendations. In non-severe second (or later) recurrences
of CDI oral vancomycin or ﬁdaxomicin is recommended.
Vancomycin and ﬁdaxomicin are equally effective in resolving
CDI symptoms, but ﬁdaxomicin has been shown to be
associated with a lower likelihood of CDI recurrence after a
ﬁrst recurrence [104,144]. However, there are no prospective
randomized controlled trials investigating the efﬁcacy of
ﬁdaxomicin in patients with multiple recurrences of CDI.
Vancomycin is preferably administered using a tapered and/or
pulsed regimen.
Recently the ﬁrst randomized controlled trial on faecal enteric
instillation has been published: faecal transplantation following
antibiotic treatment with an oral glycopeptide is reported to be
highly effective in treating multiple recurrent CDI [145].
For detailed recommendations on treatment regimens of
multiple recurrent CDI refer to Tables 21 and 22.
E: Treatment of Clostridium difﬁcile Infection
when oral Administration is not possible
Evidence
Metronidazole remains the only parenteral antibiotic therapy
supported by case series [192]. Intravenous metronidazole
(500 mg intravenous three times daily) may be added to
oral vancomycin, if the patient has ileus or signiﬁcant
abdominal distension [4,44]. However, there are no
randomized controlled trials available to guide this recom-
mendation.
It is still unknown how to best treat patients with ileus due
to CDI. There are some anecdotal reports on delivery of
vancomycin to the gut by means other than orally, mainly
through intracolonic delivery. Questions regarding the efﬁcacy,
optimal dosing and duration of treatment with intracolonic
vancomycin remain unanswered [193,194]. Prospective clinical
trials with other antibiotics, like tigecycline, have not yet been
performed to support general use [122,195].
TABLE 17. Randomized controlled trials of antibiotic treatment of initial Clostridium difﬁcile infection (CDI) in which relapses are
deﬁned and outcome of treatment is speciﬁed for CDI before study
Study Treatment
CDI before study,
No. of patients
(%)
Initial cure
No. of patients
(%)
Relapse
No. of patients
(% with initial cure)
Sustained
response ratea
No. of patients (%)
[90] Vancomycin, 125 mg four
times daily, 10 days
5/27 (19) 4/5 (80) 1/4 (25) 3/5 (60)
Nitazoxanide, 500 mg
twice daily, 10 days
2/22 (9) 2/2 (100) 1/2 (50) 1/2 (50)
[70] Vancomycin, 125 mg four
times daily, 10 days
54/309 (17) 48/54 (89) 15/48 (31) 33/54 (61)
Fidaxomicin 200 mg twice
daily, 10 days
48/287 (17) 42/48 (88) 9/42 (21) 33/42 (78)
[91] Vancomycin 125 mg four
times daily, 10 days
36/257 (14) 32/36 (89) 11/32 (34) 21/36 (58)
Fidaxomicin 200 mg twice
daily, 10 days
analysed in: [144]
40/252 (16) 37/40 (93) 7/37 (19) 30/40 (75)
aSustained response rate: clinical cure and no recurrences during follow up.
TABLE 18. Recommendations on oral antibiotic treatment of mild/moderate initial Clostridium difﬁcile infection (CDI) with risk
for recurrent CDI or ﬁrst recurrence
Treatment SoR QoE Ref(s) Comment(s)
Vancomycin, 125 mg four times
daily for 10 days
B I [70,82,90,91] No statistically signiﬁcant difference in recurrence rate between vancomycin and teicoplanin [2,82,84].
Fidaxomicin, 200 mg twice
daily for 10 days
B I [70,89,91] Evidence limited to two Phase III studies [70,91].
Retrospective subset analysis: fewer secondary recurrences with ﬁdaxomicin (n = 16/79 patients) as
compared with vancomycin (n = 26/80 patients) after treatment of a ﬁrst recurrence [144].
Fidaxomicin was not associated with fewer recurrences in CDI due to PCR ribotype 027 as opposed
to non-027 [70].
Metronidazole, 500 mg three times
daily for 10 days
C I [27,88] Recurrence rate: metronidazole not inferior to vancomycin for treatment of mild primary CDI [2,82,88]
or after a ﬁrst recurrence [27]. Vancomycin signiﬁcantly more effective in bacteriological cure than
metronidazole in recurrent CDI [69].
Vancomycin, 500 mg four times
daily for 10 days
C III [80] One randomized controlled trial on dose effectiveness in primary CDI: no signiﬁcant differences in
responses of high-dose compared with low-dose regimens vancomycin. However, results not stratiﬁed
for recurrent CDI [80].
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TABLE 19. Randomized controlled studies of treatment of recurrent Clostridium difﬁcile infection (CDI)
Trial Treatment
No. of
patients
Failurea
[%]
Faecal or bacterial instillation
[145] Vancomycin 500 mg four times daily, 14 days 13 69
Vancomycin 500 mg four times daily 14 days + bowel lavage 13 77
Vancomycin 500 mg four times daily 4 days + bowel lavage + nasoduodenal infusion donor faeces 16 19
3/16 patients with failure after ﬁrst donor faeces infusion received second infusion from a different donor: 2/3 resolved. Treatment with donor faeces was
superior to either of the vancomycin regimens (both p <0.001). Open label. No deﬁnition of diarrhoea. Study terminated by use of Haybittle–Peto rule at
unplanned interim analysis. Fecotherapy group was older, had more comorbidities, higher creatinine, and more infections with PCR ribotype 027. Other
characteristics were comparable.
Probiotics
[126] Vancomycin or metronidazole + Saccharomyces boulardii 21010 CFU/day, 4 weeks 26 35
Vancomycin or metronidazole + placebo 34 65
Double-blind. No control for type, duration or dose of antibiotic. Unclear deﬁnition of relapse. Follow up 8 weeks after start of treatment. p 0.04 for
comparison of failure rates.
[146] Vancomycin 500 mg four times daily, 10 days, followed by Saccharomyces boulardii 2 9 1010 CFU/day, 4 weeks 18 17
Vancomycin 500 mg four times daily, 10 days, followed by placebo 14 50
Vancomycin 125 mg four times daily, 10 days, followed by Saccharomyces boulardii 2 9 1010 CFU/day, 4 weeks 45 51
Vancomycin 125 mg four times daily, 10 days, followed by placebo 38 45
Metronidazole 1 g/day, 10 days, followed by Saccharomyces boulardii 2 9 1010 CFU/day, 4 weeks 27 48
Metronidazole 1 g/day, 10 days, followed by placebo 26 50
Follow up 5 months after completion of study. p 0.05 for the comparison of failure rates in patients who received 500 mg vancomycin four times daily. 22%
drop-out in this group. No further statistically signiﬁcant differences.
[147] Metronidazole 400 mg three times daily, 10 days + Lactobacillus plantarum 299v 5 9 1010 CFU/day, 38 days 12 42
Metronidazole 400 mg three times daily, 10 days + placebo 9 67
Double-blind. 28% drop-out. Follow up 70 days. Difference not statistically signiﬁcant.
[148] Vancomycin or metronidazole followed by Lactobacillus GG 6 9 1011 CFU/day, 21 days 8 38
Vancomycin or metronidazole followed by placebo 7 14
Patients blinded. No control for type, duration or dose of antibiotic. Follow up 60 days after completion of antibiotic. Difference not statistically signiﬁcant.
Passive immunotherapy with immune whey
[149] Colostral immune whey 200 mL three times daily + placebo, 14 days 18 44
Metronidazole 400 mg three times daily + placebo, 14 days 20 45
Double-blind. Multi-centre trial. Follow up 70 days. Difference not statistically signiﬁcant.
aNon-response or relapse.
TABLE 20. Observational studies for treatment of recurrent Clostridium difﬁcile infection (CDI)
Trial Treatment
No. of
patients
Failureb
(%)
Mean follow
up
Antibiotics
[150] Vancomycin taper, 21 days, followed
by vancomycin pulse, 21 days
22 0 6 months
[151] Vancomycin 125 mg four times
daily + rifampicin 600 mg twice
daily, 7 days
7 0 12 months
[69] Vancomycin 1–2 g/day 14 71 59 days
Vancomycin <1 g/day 48 54 59 days
Vancomycin ≥2 g/day 21 43 59 days
Vancomycin taper 29 31 80 days
Vancomycin pulse 7 14 80 days
Metronidazole <1 g/day 29 45 59 days
Metronidazole 1.5 g/day 5 40 59 days
Metronidazole 2 g/day 2 0 59 days
[152] Vancomycin, 14 days, followed by
rifaximin varying dose, 14 days
8 13 233 days
[153] Rifaximin 400 mg three times daily,
14 days, followed by rifaximin
200 mg three times daily, 14 days
5 0 310 days
Rifaximin 400 mg three times daily,
36 days
1 100 –
[154] Rifaximin 400 mg three times daily,
14 days
25 36 56 days
Severe CDI excluded. Patients
unresponsive to metronidazole
500 mg three times daily, 5 days.
Cure = negative stool PCR for TcdB.
All patients had resolution of diarrhoea,
but no deﬁnition or description of how
this was measured is given.
Probiotics
[155] Metronidazole or bacitracin, 10 days,
followed by Lactobacillus GG 1010
CFU/day, 7–10 days
5 20 –
[156] Lactobacillus GG 6 9 108 CFU/day, 14 days 4 0 11 months
Faecal or bacterial instillation a
[157] Faecal enema
faecal enema n = 15, enteric tube n = 1
16 19 (5 days–3 years)
[158] Faecal or bacterial enema
two faecal and four bacterial mixture
6 0 6 months
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Table 20 (Continued)
Trial Treatment
No. of
patients
Failureb
(%)
Mean follow
up
[159] Rectal tube 7 0 2 year
[160] Faecal instillation through colonoscope or
gastrostoma
18 17 –
[161] Lower gastrointestinal tract 6 0 (9–50 months)
[162] Nasogastric tube, median three courses
two patients died: not CDI-related, 15/16 cure
after ﬁrst faecal transplantation (FT), 1 relapse
16 6 90 days
[163] Faecal enema 5 0 –
[164]b Rectal catheter 45 4 (≤1 year)
[165] Colonoscopy, enema
Complete resolution of symptoms in 8/16 and
marked reduction in 7/16
16 6 6 week
[166] Vancomycin 500 mg four times daily, followed
by faecal instillation by nasoduodenal tube or
colonoscopy
7 29
0 after repeated infusion
150 days
[167] Nasogastric tube 12 17 90 days
[164]c Faecal enema
CDI in refractory inﬂammatory bowel
disease (IBD)
6 0 8 week
[168] Nasogastric tube 15 27 Median 4 months
[169] Colonoscopy 37 8 12 months
[170] Colonoscopy
1/19 non-responders after ﬁrst FT; all cured
after second FT
19 5 27 months
[171] Enema 7 0 9 months
[172] Colonoscopy 13 15 5 months
[173] Colonoscopy 12 0 (3 week–8 year)
[174] Gastroscopy or colonoscopy 40 27 80 days
[175] Colonoscopy 26 8 11 months
[176] Colonoscopy
7/77 treatment failures within 90 days after
treatment (early recurrence). 8/77
recurrence >90 days after treatment
(late recurrence).
77 19 17 months
[177] Faecal enema 27 7 427 days
[178] 5/27 patients had two FT: 2/5 failures
Faecal instillation through coloscope
Patients with (14) and without (29) IBD.
6/43 patients had two FT: 2/6 failures
43 14 2 months
[179] Colonoscopy
Initial failures were all PCR-ribotype 027.
70 11 1 year
Immunotherapy
[180] Intravenous gammaglobulin 400 mg/kg
every 3 weeks, 4–6 months
5 0 5 months
[181] Intravenous gammaglobulin 400 mg/kg day 1 and 21 4 0 7.5 months
Intravenous gammaglobulin, varying dose 5 40 2.8 months
[56] Intravenous gammaglobulin 300–500 mg/kg, 1–6 doses 5 40 86 days
[182] Intravenous gammaglobulin 150–400 mg/kg once 14 71 6.6 months
[183] Intravenous gammaglobulin 200–300 mg/kg once 18 33 (died or colectomy) –
[184] Intravenous gammaglobulin 75–400 mg/kg, 1–5 days 21 57 (died) –
Non-response or relapse.
aReviewed by Refs. [164,185–191].
bLouie (2008) abstract only derived from Ref. [164].
cBorody (2008) abstract only derived from Ref. [164].
TABLE 21. Recommendations on oral antibiotic treatment of multiple recurrent Clostridium difﬁcile infection (CDI) (more than
one relapse)
Treatment SoR QoE Ref(s) Comment(s)
Vancomycin, 125 mg four times daily
for 10 days, followed by pulse regimen
(125–500 mg/day every 2–3 days) for
at least 3 weeks.
B IIt [69,150] Retrospective case cohort of two placebo/antibiotic trials [69]: [126,146]. Observational study: [150].
Expert opinion [3].
Vancomycin, 125 mg four times daily
for 10 days, followed by taper regimen:
gradually decreasing the dose to
125 mg per day.
B IIt [69,150] Retrospective case cohort of two placebo/antibiotic trials [69]: [125,146]. Observational study: [150].
Expert opinion [3].
Fidaxomicin, 200 mg twice daily for
10 days
B IIrt [75,144] Evidence limited to two Phase III studies [70,91].
Retrospective subset analysis: fewer recurrences as compared to vancomycin treatment after ﬁrst
recurrence [144]. Systematic review: [75].
Efﬁcacy after multiple recurrences was not investigated [144].
Vancomycin, 500 mg four times daily
for 10 days
C IIrt [69,75] Retrospective case cohort of two placebo/antibiotic trials: [126,146]. Trend for lower recurrence
frequency for high-dose vancomycin [69]. Systematic review: [75].
Metronidazole, 500 mg three times daily
for 10 days
D IIrt [69,75] Retrospective case cohort of two placebo/antibiotic trials: [126,146]. Trend for lower recurrence
frequency for high-dose vancomycin and low-dose metronidazole [69]. Systematic review: [75].
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Recommendations
When oral treatment is not possible, parenteral metronidazole
is recommended, preferably combined with intracolonic or
nasogastric administration of vancomycin. Parenteral tigecy-
cline as salvage therapy is only recommended with marginal
strength. For detailed recommendations refer to Table 23.
Summary of Deﬁnitions
Episode of CDI. A clinical picture compatible with CDI and
microbiological evidence of free toxins and the presence of
C. difﬁcile in stool, without reasonable evidence of another
cause of diarrhoea.
or
Pseudomembranous colitis diagnosed during endoscopy,
after colectomy or on autopsy.
Clinical pictures compatible with CDI.
Diarrhoea: loose stools, i.e. taking the shape of the receptacle
or corresponding to Bristol stool chart types 5–7, plus a stool
frequency of three stools in 24 or fewer consecutive hours, or
more frequently than is normal for the individual.
Ileus: signs of severely disturbed bowel function such as
vomiting and absence of stool with radiological signs of bowel
distension.
Toxic megacolon: radiological signs of distension of the
colon (>6 cm in transverse width of colon) and signs of a
severe systemic inﬂammatory response.
Severe CDI. Severe or life-threatening CDI is deﬁned as an
episode of CDI with (one or more speciﬁc signs and symptoms
of) severe colitis or a complicated course of disease, with
signiﬁcant systemic toxin effects and shock, resulting in need
for ICU admission, colectomy or death.
One or more of the following unfavourable prognostic
factors can be present without evidence of another cause:
 Marked leucocytosis (leucocyte count >15 9 109/L)
 Decreased blood albumin (<30 g/L)
 Rise in serum creatinine level (≥133 lM or ≥1.5 times the
premorbid level)
Recurrent CDI. Recurrence is present when CDI re-occurs
<8 weeks after the onset of a previous episode, provided the
symptoms from the previous episode resolved after comple-
tion of initial treatment.
Treatment response. Treatment response is present when after
therapy either stool frequency decreases or stool consistency
improves and parameters of disease severity (clinical, labora-
tory, radiological) improve and no new signs of severe disease
develop.
Treatment response should be observed daily and evaluated
after at least 3 days, assuming that the patient is not worsening
on treatment. Treatment with metronidazole, in particular,
may result in a clinical response only after 3–5 days. After
clinical response, it may take weeks for stool consistency and
frequency to become entirely normal.
TABLE 22. Recommendations on non-antibiotic treatment (in combination with antibiotic treatment) of recurrent Clostridium
difﬁcile infection (CDI) (more than one relapse)
Type of intervention Treatment SoR QoE Ref(s) Comment(s)
Faecal or bacterial instillation Vancomycin, 500 mg four times daily,
4 days + bowel lavage + nasoduodenal
infusion donor faeces
A I [145] Also many observational studies and meta-analyses. [164,186,189–191].
Probiotics Vancomycin or metronidazole +
Saccharomyces boulardii
D I [126] Comparison of relapse rates: in subgroup analysis efﬁcacy in recurrent
CDI, but not in initial CDI. Evidence-based review: [137].
Vancomycin or metronidazole +
Lactobacillus spp.
D I [147,148] Evidence-based review: [137].
Passive immunotherapy with
immune whey
Colostral immune whey D I [149] Study interrupted early.
TABLE 23. Recommendations on non-oral antibiotic treatment of initial Clostridium difﬁcile infection (CDI): mild and severe
disease
Patient subgroup Treatment SoR QoE Ref(s) Comment(s)
Non-severe disease Intravenous metronidazole 500 mg three times daily for 10 days A IIu [192] Retrospective uncontrolled study [192].
Severe disease and/or
complicated
or refractory CDI
Intravenous metronidazole 500 mg three times daily for 10 days +
vancomycin retention enema 500 mg in 100 mL normal saline
four times daily intracolonic for 10 days
A
B
IIru
III
[192–194] Retrospective uncontrolled study [192].
Systematic review [193,194].
Expert opinion [3].
Intravenous metronidazole 500 mg three times daily for 10 days +
vancomycin 500 mg in 100 mL normal saline four times daily
by oral/nasogastric tube for 10 days
A
B
IIru
III
[192–194] Retrospective uncontrolled study [192].
Systematic review [193,194].
Expert opinion [3].
Intravenous tigecycline 50 mg twice daily for 14 days C III [122] Observational study/case report [122].
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Summary of Treatment Recommendations
Strength of Evidence (SoE: I to III) and Strength of Recom-
mendation (SoR: A to D) are shown in brackets. For grading
deﬁnitions we refer to Tables 1 and 2.
A: Initial Clostridium difﬁcile Infection:
non-severe Disease
Non-antibiotic treatment
In non-epidemic situations and with (non-severe) CDI
clearly induced by the use of antibiotics, it may be
acceptable to stop the inducing antibiotic and observe the
clinical response for 48 h, but patients must be followed
very closely for any signs of clinical deterioration and placed
on therapy immediately if this occurs. (C-II).
Oral antibiotic treatment
Metronidazole orally 500 mg three times daily for 10 days
(A-I)
Vancomycin orally 125 mg four times daily for 10 days (B-I)
Fidaxomicin orally 200 mg twice daily for 10 days (B-I)
B: Severe Clostridium difﬁcile Infection
Oral antibiotic treatment
Vancomycin orally 125 mg four times daily for 10 days
(A-I)
Fidaxomicin orally 200 mg twice daily for 10 days (B-I)
Notes:
 It can be considered to increase the vancomycin dosage to
500 mg four times daily for 10 days (B-III)
 There is no evidence that supports the use of ﬁdaxomicin in
life-threatening CDI (D-III)
The use of oral metronidazole in severe CDI or life-threat-
ening disease is strongly discouraged (D-I).
Surgical treatment
Total abdominal colectomy with ileostomy should be per-
formed in case of:
 Perforation of the colon
 Systemic inﬂammation and deteriorating clinical condition
not responding to antibiotic therapy; including toxic mega-
colon, an acute abdomen and severe ileus.
Surgical treatment should preferably be performed before
colitis becomes very severe. Serum lactate may, inter alia,
serve as a marker for severity (operate before lactate exceeds
5.0 mM).
A future alternative to colectomy may be diverting loop
ileostomy and colonic lavage, combined with antibiotic treat-
ment (intracolonic antegrade vancomycin and intravenous
metronidazole).
C: First Recurrence or (Risk of) recurrent
Clostridium difﬁcile Infection
Oral antibiotic treatment
Fidaxomicin orally 200 mg twice daily for 10 days (B-I)
Vancomycin orally 125 mg four times daily for 10 days (B-I)
Metronidazole orally 500 mg three times daily for 10 days
(C-I)
Note: Fidaxomicin was not associated with fewer recur-
rences in CDI due to PCR ribotype 027 as opposed to
non-027 ribotypes.
D: Multiple recurrent Clostridium difﬁcile
Infection
Oral antibiotic treatment
Fidaxomicin orally 200 mg twice daily for 10 days (B-II)
Vancomycin orally 125 mg four times daily for 10 days
followed by pulse strategy (B-II)
or
Vancomycin orally 125 mg four times daily for 10 days
followed by taper strategy (B-II)
Non-antibiotic treatment in combination with oral antibiotic
treatment
For multiple recurrent CDI unresponsive to repeated
antibiotic treatment, faecal transplantation in combination
with oral antibiotic treatment is strongly recommended
(A-I).
E: Treatment of Clostridium difﬁcile Infection
when oral Administration is not possible
Antibiotic treatment
Non-severe CDI: intravenous metronidazole 500 mg three
times daily for 10 days (A-II).
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Severe CDI: intravenous metronidazole 500 mg three times
daily for 10 days (A-II) combined with vancomycin retention
enema 500 mg in 100 mL normal saline four times daily
intracolonic, or combined with vancomycin 500 mg four times
daily by oral/nasogastric tube for 10 days (B-III).
A schematic overview of currently available therapeutic
regimens for CDI, including the quality of evidence (QoE: I to
III) and strength of recommendations (SoR: A to D) are shown
in Fig. 1.
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